Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Identifieur interne : 001560 ( PubMed/Corpus ); précédent : 001559; suivant : 001561Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Auteurs : F. Tison ; L. Wiart ; M. Guatterie ; N. Fouillet ; V. Lozano ; P. Henry ; M. BaratSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1996.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Apomorphine (administration & dosage), Apomorphine (adverse effects), Brain (drug effects), Brain (physiopathology), Deglutition Disorders (drug therapy), Deglutition Disorders (physiopathology), Domperidone (administration & dosage), Domperidone (adverse effects), Dopamine Antagonists (administration & dosage), Dopamine Antagonists (adverse effects), Drug Therapy, Combination, Female, Fluoroscopy, Humans, Injections, Subcutaneous, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Video Recording.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Apomorphine, Domperidone, Dopamine Antagonists.
- chemical , adverse effects : Antiparkinson Agents, Apomorphine, Domperidone, Dopamine Antagonists.
- drug effects : Brain, Receptors, Dopamine.
- drug therapy : Deglutition Disorders, Parkinson Disease.
- chemical , physiology : Receptors, Dopamine.
- physiopathology : Brain, Deglutition Disorders, Parkinson Disease.
- Aged, Drug Therapy, Combination, Female, Fluoroscopy, Humans, Injections, Subcutaneous, Male, Middle Aged, Video Recording.
Abstract
Swallowing disorders are common in Parkinson's disease but are of obscure and complex nature and pathophysiology. The effect of central dopaminergic stimulation on disordered swallowing is not well known. We studied the effects of apomorphine (in combination with domperidone) on buccolinguofacial motoricity and on various swallowing stages by using videofluoroscopy in eight patients with dysphagia. Swallowing abnormalities more frequently encountered were vallecular stasis (n = 7), fragmentation of the bolus (n = 7), and buccal stagnation of the bolus. Apomorphine improved vallecular stasis and fragmentation in about half the cases and improved buccal stagnation in all cases. Direct laryngeal penetration was found in three cases and improved in two of them. The total swallowing duration was improved by apomorphine in a subset of patients (n = 5). This improvement correlated with an improvement of the buccolinguofacial motoricity and was combined with an improvement of pharyngeal transit time. Thus central dopaminergic stimulation by apomorphine improved swallowing in a subgroup of patients, mainly in its early stages.
DOI: 10.1002/mds.870110622
PubMed: 8914103
Links to Exploration step
pubmed:8914103Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.</title><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation><nlm:affiliation>Département de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wiart, L" sort="Wiart, L" uniqKey="Wiart L" first="L" last="Wiart">L. Wiart</name></author><author><name sortKey="Guatterie, M" sort="Guatterie, M" uniqKey="Guatterie M" first="M" last="Guatterie">M. Guatterie</name></author><author><name sortKey="Fouillet, N" sort="Fouillet, N" uniqKey="Fouillet N" first="N" last="Fouillet">N. Fouillet</name></author><author><name sortKey="Lozano, V" sort="Lozano, V" uniqKey="Lozano V" first="V" last="Lozano">V. Lozano</name></author><author><name sortKey="Henry, P" sort="Henry, P" uniqKey="Henry P" first="P" last="Henry">P. Henry</name></author><author><name sortKey="Barat, M" sort="Barat, M" uniqKey="Barat M" first="M" last="Barat">M. Barat</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1996">1996</date><idno type="RBID">pubmed:8914103</idno><idno type="pmid">8914103</idno><idno type="doi">10.1002/mds.870110622</idno><idno type="wicri:Area/PubMed/Corpus">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.</title><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation><nlm:affiliation>Département de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wiart, L" sort="Wiart, L" uniqKey="Wiart L" first="L" last="Wiart">L. Wiart</name></author><author><name sortKey="Guatterie, M" sort="Guatterie, M" uniqKey="Guatterie M" first="M" last="Guatterie">M. Guatterie</name></author><author><name sortKey="Fouillet, N" sort="Fouillet, N" uniqKey="Fouillet N" first="N" last="Fouillet">N. Fouillet</name></author><author><name sortKey="Lozano, V" sort="Lozano, V" uniqKey="Lozano V" first="V" last="Lozano">V. Lozano</name></author><author><name sortKey="Henry, P" sort="Henry, P" uniqKey="Henry P" first="P" last="Henry">P. Henry</name></author><author><name sortKey="Barat, M" sort="Barat, M" uniqKey="Barat M" first="M" last="Barat">M. Barat</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1996" type="published">1996</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (adverse effects)</term><term>Brain (drug effects)</term><term>Brain (physiopathology)</term><term>Deglutition Disorders (drug therapy)</term><term>Deglutition Disorders (physiopathology)</term><term>Domperidone (administration & dosage)</term><term>Domperidone (adverse effects)</term><term>Dopamine Antagonists (administration & dosage)</term><term>Dopamine Antagonists (adverse effects)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Fluoroscopy</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Video Recording</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Domperidone</term><term>Dopamine Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Domperidone</term><term>Dopamine Antagonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Deglutition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Deglutition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Therapy, Combination</term><term>Female</term><term>Fluoroscopy</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Video Recording</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Swallowing disorders are common in Parkinson's disease but are of obscure and complex nature and pathophysiology. The effect of central dopaminergic stimulation on disordered swallowing is not well known. We studied the effects of apomorphine (in combination with domperidone) on buccolinguofacial motoricity and on various swallowing stages by using videofluoroscopy in eight patients with dysphagia. Swallowing abnormalities more frequently encountered were vallecular stasis (n = 7), fragmentation of the bolus (n = 7), and buccal stagnation of the bolus. Apomorphine improved vallecular stasis and fragmentation in about half the cases and improved buccal stagnation in all cases. Direct laryngeal penetration was found in three cases and improved in two of them. The total swallowing duration was improved by apomorphine in a subset of patients (n = 5). This improvement correlated with an improvement of the buccolinguofacial motoricity and was combined with an improvement of pharyngeal transit time. Thus central dopaminergic stimulation by apomorphine improved swallowing in a subgroup of patients, mainly in its early stages.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8914103</PMID><DateCreated><Year>1997</Year><Month>03</Month><Day>20</Day></DateCreated><DateCompleted><Year>1997</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>1996</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>729-32</MedlinePgn></Pagination><Abstract><AbstractText>Swallowing disorders are common in Parkinson's disease but are of obscure and complex nature and pathophysiology. The effect of central dopaminergic stimulation on disordered swallowing is not well known. We studied the effects of apomorphine (in combination with domperidone) on buccolinguofacial motoricity and on various swallowing stages by using videofluoroscopy in eight patients with dysphagia. Swallowing abnormalities more frequently encountered were vallecular stasis (n = 7), fragmentation of the bolus (n = 7), and buccal stagnation of the bolus. Apomorphine improved vallecular stasis and fragmentation in about half the cases and improved buccal stagnation in all cases. Direct laryngeal penetration was found in three cases and improved in two of them. The total swallowing duration was improved by apomorphine in a subset of patients (n = 5). This improvement correlated with an improvement of the buccolinguofacial motoricity and was combined with an improvement of pharyngeal transit time. Thus central dopaminergic stimulation by apomorphine improved swallowing in a subgroup of patients, mainly in its early stages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tison</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiart</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Guatterie</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fouillet</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Barat</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="N">Deglutition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004294" MajorTopicYN="N">Domperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005471" MajorTopicYN="N">Fluoroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014741" MajorTopicYN="N">Video Recording</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8914103</ArticleId><ArticleId IdType="doi">10.1002/mds.870110622</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:8914103
|texte= Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8914103" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |